Search

BACKGROUND: Oleuropein is a natural antioxidant and scavenging free radicals. In the present study, we examined effect of oleuropein on the paraoxonase 1 (PON1) activity, lipid peroxidation, lipid profile, atherogenic indexes, and relationship of PON1 activity by high-density lipoprotein-cholesterol (HDL-C) and atherogenic indices in gentamicin (GM)-induced nephrotoxicity in rats. METHODS: This is a lab trial study in Khorramabad, Lorestan province of Iran (2013). 30 Sprague-Dawley rats were divided into three groups to receive saline; GM, 100 mg/kg/day; and GM plus oleuropein by 15 mg/kg intraperitoneal daily, respectively. After 12 days, animals were anesthetized, blood samples were also collected before killing to measure the levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), and very LDL (VLDL), HDL-C, atherogenic index, lipid peroxidation, and the activities of PON1 of all groups were analyzed. Data were analyzed, and P < 0.050 was considered significant. RESULTS: Oleuropein significantly decreased lipid peroxidation, TG, TC, LDL, VLDL, atherogenic index, atherogenic coefficient (AC), and cardiac risk ratio (CRR). HDL-C level was significantly increased when treated with oleuropein. The activity of PON1 in treated animals was (62.64 ± 8.68) that it was significantly higher than untreated animals (47.06 ± 4.10) (P = 0.047). The activity of PON1 in the untreated nephrotoxic rats was significantly lower than that of control animals (77.84 ± 9.43) (P = 0.030). Furthermore, the activity of PON1 correlated positively with HDL-C and negatively with AC, CRR 1, and CRR 2 in the treated group with oleuropein. CONCLUSION: This study showed that oleuropein improves PON1 activity, lipid profile, and atherogenic index and can probably decrease the risk of cardiovascular death in nephrotoxic patients.

Abstract:BACKGROUND: The prevalence of Congestive Heart Failure (CHF) is increasing in recent years. Factors associated with mortality in CHF patients are important to be determined in order to select therapeutic modality by physicians. The purpose of the current study was to declare predictors of 6-months survival in patients hospitalized for decompensated CHF in Isfahan.METHODS: A cohort of 301 hospitalized patients with decompensated CHF were recruited in this study. The diagnosis of CHF was based on previous hospitalizations and Framingham criteria for heart failure (HF). Information regarding past history, accompanying diseases such as cerebrovascular accidents (CVA), chronic obstructive pulmonary diseases (COPD), clinical data, medications and echocardiography were obtained by a cardiologist. Patients were followed for their survival for 6 months by telephone calls. Kaplan-Meier method was used for uni variate survival analysis and Cox proportional hazard model was used for multivariate analysis.RESULTS: Mean age of patients was 71.9 ± 12.2 years and 59.8% was male. During 6-months follow-up 138 (45.8%) patients died. Mean survival was 119.2 ± 4.4 days (Mean ± SEM). Significant prognostic factors for 6 months survival were high education level (HR = 0.74, CI 95% 0.59—0.93), COPD (HR = 1.91, CI 95% 1.2—3.04), CVA (HR = 1.69, CI 95% 1.03—2.78), Angiotensin Converting enzyme (ACE) inhibitors use (HR = 0.44, CI 95% 0.3—0.66) and Diuretics (HR = 0.63, CI 95% 0.41-0.96).CONCLUSION: Six-month survival of hospitalized decompensated CHF patients in Iran is not favorable. Many factors particularly accompanying diseases and medications affected the patient’s 6-months survival.Keywords: Heart failure, Survival, Mortality.